Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Navidea Biopharma (NAVB) Reports Q1 Loss of $0.13
May 14, 2020 4:25 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q1 EPS of ($0.13), versus ($0.24) reported last year. Revenue for the quarter came in at $155.66 thousand, versus $41.62 thousand reported last year.
First Quarter 2020 Highlights and Subsequent Events
Continued with double-digit subject enrollment in the Companys NAV3-31 Phase 2b study in rheumatoid arthritis (RA) and completed enrollment of subjects in Arms 1 and 2.Continued enrollment in the Investigator Initiated Phase 2 trial being run at the Massachusetts General Hospital evaluating Tc99m tilmanocept uptake in atherosclerotic plaques of HIV-infected individuals.Announced extension by the U.S. Patent and... More